CADI-R503

CADI-R503 is an oncology research and development program initiated by Bio-Modeling Systems (BMSystems). It utilizes the company's proprietary CADI™ (Computer-Aided Design for In silico discovery) platform, which employs a systems biology approach to model complex, non-linear disease mechanisms. The CADI-R503 program specifically targets solid tumors, aiming to identify novel therapeutic protocols—often involving synergistic drug combinations or repurposed agents—that can disrupt the robust biological networks driving malignancy. The program represents a completed in silico discovery phase, meaning the mechanistic model and proposed therapeutic strategy have been defined and are positioned for preclinical validation and further development.